相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data
Masataka Kuwana et al.
MODERN RHEUMATOLOGY (2023)
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
Lotte van Ouwerkerk et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies
S. Sajith Kumar et al.
CLINICAL DRUG INVESTIGATION (2023)
Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
Bhavani Shankara Bagepally et al.
BMC HEALTH SERVICES RESEARCH (2022)
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
Bhavani Shankara Bagepally et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost-utility studies
Bhavani Shankara Bagepally et al.
BMJ OPEN GASTROENTEROLOGY (2022)
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis
Chongqing Tan et al.
CLINICAL RHEUMATOLOGY (2022)
Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
S. Sajith Kumar et al.
FRONTIERS IN PHARMACOLOGY (2022)
Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
Akhil Sasidharan et al.
PLOS ONE (2022)
Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
Shaalina Nair et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience
Behzad Fatemi et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis
Elena Lopatina et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
Aliza R. Karpes Matusevich et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2021)
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review
Peter C. Taylor et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population
Chongqing Tan et al.
ADVANCES IN THERAPY (2021)
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
Ahmad Gholami et al.
Biomed Research International (2021)
Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
Prapaporn Noparatayaporn et al.
OBESITY SURGERY (2021)
Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
SiNi Li et al.
RHEUMATOLOGY AND THERAPY (2021)
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
SiNi Li et al.
RHEUMATOLOGY AND THERAPY (2021)
Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
Feng Tian et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment With Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan
Tomohiro Hirose et al.
Value in Health Regional Issues (2021)
Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients
Zhi-Chao Shi et al.
MEDICINE (2020)
Cost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial
Anita Patel et al.
ARTHRITIS CARE & RESEARCH (2020)
Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France
Salah Ghabri et al.
VALUE IN HEALTH (2020)
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
F. Navarro et al.
CLINICAL RHEUMATOLOGY (2020)
Why it's Time to Abandon the ICER
Mike Paulden
PHARMACOECONOMICS (2020)
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
Bhavani Shankara Bagepally et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
Elise van Mulligen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
Devin Incerti et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2020)
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
Celine J. Van De Laar et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2020)
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Noemi Muszbek et al.
ADVANCES IN THERAPY (2019)
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
Der-Yuan Chen et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
Saara Huoponen et al.
PLOS ONE (2019)
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Noemi Muszbek et al.
Journal of Managed Care & Specialty Pharmacy (2019)
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis
Melanie D. Whittington et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2019)
Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
Bhavani Shankara Bagepally et al.
VALUE IN HEALTH (2019)
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
Marie Fournier et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
Max Schlueter et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States
Lindsay Claxton et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
Sarah Brown et al.
HEALTH TECHNOLOGY ASSESSMENT (2018)
Early Diagnosis and Treatment of Rheumatoid Arthritis
Emily A. Littlejohn et al.
PRIMARY CARE (2018)
Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis
Evo Alemao et al.
VALUE IN HEALTH (2018)
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial
An Tran-Duy et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
Vladimira V. Boyadzieva et al.
FRONTIERS IN PHARMACOLOGY (2018)
Diagnosis and Management of Rheumatoid Arthritis A Review
Daniel Aletaha et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan
Eiichi Tanaka et al.
MODERN RHEUMATOLOGY (2017)
The GRADE Working Group clarifies the construct of certainty of evidence
Monica Hultcrantz et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
C. Tzanetakos et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China
Jingyang Li et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2017)
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators
Jeroen P. Jansen et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
Erkki Soini et al.
ADVANCES IN THERAPY (2017)
Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis A Cost-Effectiveness Analysis
Nick Bansback et al.
ANNALS OF INTERNAL MEDICINE (2017)
Risk of bias in model-based economic evaluations: the ECOBIAS checklist
Charles Christian Adarkwah et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
Wietske Kievit et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea
Sun-Kyeong Park et al.
CLINICAL THERAPEUTICS (2016)
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
Matt Stevenson et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
Jaana T. Joensuu et al.
RHEUMATOLOGY (2016)
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
C. Gissel et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2016)
Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis
Hawre Jalal et al.
ARTHRITIS CARE & RESEARCH (2016)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
Min-Young Lee et al.
CLINICAL THERAPEUTICS (2015)
Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies
Maria K. Kvamme et al.
RHEUMATOLOGY (2015)
THE LIMITATIONS OF ICERS IN SCREENING INTERVENTIONS AND THE RELATIVE NET BENEFIT ALTERNATIVE
J. F. O'Mahony
VALUE IN HEALTH (2015)
Economic Evaluation of Tocilizumab Monoth.erapy Compared to Adalimumab Monoth.erapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson et al.
VALUE IN HEALTH (2015)
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
Sofie H. M. Manders et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
Stephanie Stephens et al.
BMJ OPEN (2015)
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects
C. L. M. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
Jonas K. Eriksson et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
Alvaro Hidalgo-Vega et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2015)
Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved
Gisela Kobelt
VALUE IN HEALTH (2014)
Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia
Carolina Valle-Mercado et al.
RHEUMATOLOGY INTERNATIONAL (2013)
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
Ingrid Lekander et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China
Bin Wu et al.
PLOS ONE (2012)
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis An Application of Bayesian Methods for Evidence Synthesis in a Markov Model
Christine M. Nguyen et al.
PHARMACOECONOMICS (2012)
Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
Alexander Diamantopoulos et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
K. Malottki et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment
Gisela Kobelt et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective
Lydia G. Schipper et al.
RHEUMATOLOGY (2011)
Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life
Maurizio Benucci et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis
E. J. Soini et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden
Ingrid Lekander et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
Taru A. Hallinen et al.
RHEUMATOLOGY (2010)
Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure
Sonja Merkesdal et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2010)
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Peter Lindgren et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis
Andrew Davies et al.
JOURNAL OF RHEUMATOLOGY (2009)
Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study
H. Schulze-Koops et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2009)
Biologic drugs for rheumatoid arthritis in the medicare program
Allan J. Wailoo et al.
ARTHRITIS AND RHEUMATISM (2008)
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug
Adrian Kielhorn et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Registry
A. Brennan et al.
RHEUMATOLOGY (2007)
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Y-F Chen et al.
HEALTH TECHNOLOGY ASSESSMENT (2006)
A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics
Pendar Farahani et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2006)
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis
James R. Spalding et al.
PHARMACOECONOMICS (2006)
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
G Kobelt et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
NJ Bansback et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK
M Barbieri et al.
PHARMACOECONOMICS (2005)
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
A Brennan et al.
RHEUMATOLOGY (2004)
Etanercept - A pharmacoeconomic review of its use in rheumatoid arthritis
KA Lyseng-Williamson et al.
PHARMACOECONOMICS (2004)
The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
G Kobelt et al.
RHEUMATOLOGY (2003)
Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
JB Wong et al.
AMERICAN JOURNAL OF MEDICINE (2002)
分享论文
